|Articles|August 1, 2002

Measuring Persistency with Drug Therapy in Glaucoma Management
Volume 8
Issue 10 Suppl

Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population

Author(s)Fadia T. Shaya, PhD, MPH, C. Daniel Mullins, PhD, Winston Wong, PharmD

Download PDF: Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population

Articles in this issue

over 23 years ago

Article

Measuring Patient Persistency with Drug Therapy Using Methods for the Design and Analysis of Natural History Studies

over 23 years ago

Article

Participating Faculty

over 23 years ago

Article

Introduction

over 23 years ago

Article

An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension

over 23 years ago

Article

Population-Based Persistency Rates for Topical Glaucoma Medications Measured with Pharmacy Claims Data

over 23 years ago

Article

Rates of Discontinuation and Change of Glaucoma Therapy in a Managed Care Setting

over 23 years ago

Article

Measuring Persistency and Intraocular Pressure-Controlled Days in Patients Receiving Topical Glaucoma Medications

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

ByMohamed M. Ali, MS,Scott Lunos, MS,Zachary Henderson, BSB,Michele Allen, MD, MS,Patricia Adam, MD, MSPH,Genevieve B. Melton, MD, PhD,Rubina Rizvi, MD, PhD

January 12th 2026

Subjective and Objective Impacts of Ambulatory AI Scribes

ByJulia Adler-Milstein, PhD,Orianna DeMasi, PhD,Hossein Soleimani, PhD,Sarah Beck, MDiv,Maria E. Byron, MD,Aris Oates, MD,Robert Thombley, BS,Jinoos Yazdany, MD, MPH,Sara G. Murray, MD, MAS

January 8th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population

Articles in this issue

Newsletter

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

Subjective and Objective Impacts of Ambulatory AI Scribes

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Congress Unveils Massive Funding Bill to Avert Shutdown

ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC

Novel CLL Therapies Prompt New Treatment Considerations

Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD